Filing scope and business context
The supplied filing is Galapagos NV’s audited Form 20-F annual report for the fiscal year ended December 31, 2017, not a quarterly filing. The request metadata identifies “Lakefront Biotherapeutics NV,” but the filing text consistently identifies the registrant as Galapagos NV; this discrepancy should be verified. Galapagos is a Belgian clinical-stage biopharmaceutical company with no approved products or product-sales revenue. Its principal programs address inflammatory diseases, cystic fibrosis, idiopathic pulmonary fibrosis, osteoarthritis and atopic dermatitis.
The financial statements are presented in euros and prepared under IFRS as issued by the IASB. Galapagos had 50,936,778 ordinary shares outstanding at December 31, 2017 and approximately 600 employees.
2017 financial performance and liquidity
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Revenue | €127.1 million | €129.5 million | (2%) |
| Other income | €28.8 million | €22.1 million | 30% |
| Total revenue and other income | €155.9 million | €151.6 million | 3% |
| Research and development expense | €218.5 million | €139.6 million | 57% |
| Total operating expenses | €245.7 million | €163.1 million | 51% |
| Operating loss | €89.8 million | €11.5 million | Higher loss |
| Net income/(loss) | €(115.7) million | €54.0 million | Returned to loss |
| Basic loss/(income) per share | €(2.34) | €1.18 | Unfavorable change |
| Net cash used in operating activities | €147.0 million | €239.4 million generated | €386.4 million unfavorable |
| Cash and cash equivalents at year-end | €1,151.2 million | €973.2 million | €178.0 million increase |
Revenue consisted primarily of collaboration-related upfront and license-fee recognition (€72.0 million), milestone payments (€43.0 million), reimbursement income (€3.3 million) and other revenue (€8.9 million). The company recognized €62.5 million of the Gilead filgotinib upfront payment and €8.8 million related to deferred income from the share subscription agreement.
R&D spending increased principally because of higher clinical-development and subcontracting costs. Program spending included €53.2 million for filgotinib, €46.2 million for cystic fibrosis, €16.2 million for GLPG1690 in IPF, €7.3 million for GLPG1972 in osteoarthritis and €8.4 million for MOR106 in atopic dermatitis.
Other financial expenses were €30.6 million, including a €29.2 million foreign-exchange loss, primarily associated with U.S.-dollar cash balances. The company reported no long-term debt other than finance leases and stated that it had no credit lines.
Material changes versus 2016
- Operating losses widened substantially as R&D investment increased 57%, while revenue declined 2%.
- The 2016 net profit was materially affected by a €57.5 million non-cash fair-value gain related to the Gilead share subscription agreement; no comparable gain occurred in 2017.
- Operating cash flow changed from a €239.4 million inflow in 2016, driven largely by the Gilead upfront payment, to a €147.0 million outflow in 2017.
- Financing activities generated €353.4 million in 2017, primarily from a U.S. public offering that produced €348.1 million of net proceeds. Gilead’s 2016 equity investment produced €391.9 million of net proceeds.
- Sales and marketing expense rose 57% as Galapagos began building a commercial organization for potential filgotinib co-promotion.
- Cash increased despite operating cash burn because of the 2017 equity offering. Total equity rose to €1,012.0 million from €758.7 million.
Guidance, outlook, risks and unusual items
Management stated that existing cash and cash equivalents were expected to fund operating expenses and capital expenditures for at least two to three years, based on assumptions that may prove incorrect. The company expects continued significant losses and does not anticipate product-sales revenue for the foreseeable future, if ever.
- Gilead’s filgotinib program was in Phase 3 trials in rheumatoid arthritis and Crohn’s disease and a Phase 2b/3 trial in ulcerative colitis. Galapagos expected additional 2018 trial milestones and topline data.
- Galapagos expected to advance GLPG1690 into pivotal IPF trials, initiate patient testing of a first triple-combination CF therapy, begin a global Phase 2 osteoarthritis program for GLPG1972 and initiate a Phase 2 atopic-dermatitis trial for MOR106.
- The company is heavily dependent on the clinical, regulatory and commercial success of filgotinib and on collaboration partners Gilead and AbbVie. No product candidate had received regulatory approval.
- Clinical, regulatory, manufacturing, intellectual-property and market-acceptance risks could delay or prevent commercialization. A European opposition proceeding had been filed against a granted patent covering filgotinib compositions.
- Contractual obligations totaled €91.6 million, including €26.3 million of operating leases and €65.2 million of purchase commitments. The separate contractual cost-sharing commitment under the Gilead collaboration was €129.0 million at year-end.
- A former subsidiary director’s wrongful-termination claim sought €1.5 million. Management assessed the claim as possible but not likely and recorded no provision.
- Four claims by Charles River related to the former service division had been settled for €1.3 million; the remaining €6.6 million escrow balance was released in 2017.
- The company disclosed that adoption of IFRS 15 in 2018 could affect revenue recognition, but the filing did not provide a final quantified impact.
Most important facts for investors to verify
- Confirm the issuer identity: the source filing is for Galapagos NV, whereas the request metadata names Lakefront Biotherapeutics NV.
- Confirm the requested period: the filing covers the full year ended December 31, 2017, not “2017 Q4” financial results.
- Reconcile revenue recognition from Gilead’s upfront payment and the €219.9 million deferred-income balance at year-end.
- Assess the sustainability of the €147.0 million annual operating cash burn against the company’s stated two-to-three-year liquidity horizon and €129.0 million Gilead cost-sharing commitment.
- Evaluate reliance on filgotinib, Gilead and AbbVie, including trial outcomes, regulatory restrictions, collaboration termination rights and future milestone assumptions.
- Review foreign-exchange exposure, particularly the $241.3 million of U.S.-dollar cash and the €29.2 million 2017 currency-exchange loss.
- Review patent opposition, clinical-trial safety data, regulatory approval status and the absence of approved products or product-sales revenue.
- Verify the status and potential exposure of the €1.5 million employment litigation claim and other contractual commitments.